Arcutis Biotherapeutics

Delivering meaningful innovation to address the most persistent challenges in medical #dermatology drug development. $ARQT #DermTwitter #Immunodermatology.

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we announced the publication of age-specific expert recommendations to help improve the recognition, diagnosis and management of genital #psoriasis across pediatric, adult, and older populations.

Read more: https://t.co/QJQz3k6R6O

#ClinicalDermatology

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today, we announced #Q1 2026 financial results and provided a business update. Read our release for full details: https://t.co/m3vjwhjeFE

$ARQT

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we submitted an application to the @US_FDA to expand the indication for our topical treatment for #AtopicDermatitis to include infants ages 3-24 months.

Learn more: https://t.co/VlKHoHxT9L

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we announced that our topical cream has received a strong recommendation in @AADskin's first-ever guidelines for children and adolescents with mild to moderate #AtopicDermatitis.

Learn more: https://t.co/b9gQLlei0N

#ClinicalDermatology

[Arcutis Biotherapeutics @ArcutisBio]

Today, Arcutis President and CEO Frank Watanabe and Chief Financial Officer Latha Vairavan will be participating in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference. More details below.

#ClinicalDermatology

[Arcutis Biotherapeutics @ArcutisBio]

Advanced targeted topicals are expanding options for people with chronic inflammatory #SkinDiseases. Arcutis President and CEO Frank Watanabe and CMO Patrick Burnett explain how these therapies may help address a long-sought balance between treatment goals. Watch to learn more.

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we announced the presentation of new, late-breaking data from our INTEGUMENT-INFANT trial in #AtopicDermatitis at @AADskin’s 2026 Annual Meeting.

Learn more: https://t.co/0v0b4QvPXb

#AAD2026 #ClinicalDermatology #ArcutisAtAAD

[Arcutis Biotherapeutics @ArcutisBio]

#ICYMI: We’re back at @AADskin’s 2026 Annual Meeting and will be sharing data from our investigational studies in #AtopicDermatitis, #SeborrheicDermatitis, and #Psoriasis. Come see us at booth #540. Learn more: https://t.co/xLDd5cVwi6

#AAD2026 #ClinicalDermatology #ArcutisAtAAD

[Arcutis Biotherapeutics @ArcutisBio]

Our 2025 annual report and shareholder letter are now available. Our achievements in 2025 strengthened Arcutis’ position as a leading medical dermatology company. Building on this momentum, we'll continue to grow, expand, and build in 2026.

Read more: https://t.co/AyuDb8LJVs

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: We’re excited to be back at @AADskin’s 2026 Annual Meeting and look forward to sharing data from our studies in #AtopicDermatitis, #SeborrheicDermatitis, and #Psoriasis.

Learn more: https://t.co/xLDd5cVwi6

#AAD2026 #ClinicalDermatology #ArcutisAtAAD

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Pediatric Dermatology published long-term results from the Phase 3 open-label extension study of our once-daily topical cream for the treatment of mild-to-moderate #AtopicDermatitis in children aged 2-5 years.

Read more: https://t.co/gvMKcD8qKS

#PediatricDermatology

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: We’re thrilled to announce Mas Matsuda, JD’s promotion to EVP and Chief Legal Officer! His leadership and trusted counsel have helped support our growth, and we look forward to his continued impact in this new role. Congratulations, Mas!

Read more: https://t.co/MRRPseWQ0k

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today we announced the enrollment of the first individual in a Phase 1 study evaluating ARQ-234, a potential biologic treatment for moderate to severe #AtopicDermatitis.

Learn more: https://t.co/Lb1NGElw4G

#ClinicalDermatology

[Arcutis Biotherapeutics @ArcutisBio]

Tomorrow, Arcutis President and CEO Frank Watanabe and Chief Commercial Officer Todd Edwards will be participating in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston. More details below.

#ClinicalDermatology $ARQT

[Arcutis Biotherapeutics @ArcutisBio]

Arcutis is in Philadelphia for the 2026 @AAAAI_org Annual Meeting, where we’ll be presenting data and connecting with colleagues across the community. We look forward to advancing #MeaningfulInnovation in patient care.

#AAAAI26 #ClinicalDermatology

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today, we announced #Q4 2025 and full year 2025 financial results. Read our release for full details and business updates: https://t.co/waUilwSUv2

$AQRT

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Excited to tee-off our partnership with pro-golfer, Max Homa, as part of our Free to Be Me campaign! Learn more about this campaign and Max's journey to manage his seb derm: https://t.co/R5ppE4GyJn

#ClinicalDermatology #SebDerm

[Arcutis Biotherapeutics @ArcutisBio]

Arcutis CMO Patrick Burnett, MD, PhD, FAAD and CFO Latha Vairavan are participating in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit this week in New York City. Details below.

#ClinicalDermatology $ARQT

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today, we shared topline results from the INTEGUMENT-INFANT #ClinicalTrial evaluating our topical cream in infants ages 3-24 months with mild to moderate #AtopicDermatitis.

Learn more: https://t.co/RoDiBDsQVm

[Arcutis Biotherapeutics @ArcutisBio]

#NEWS: Today, we announced that Arcutis and Kowa have mutually agreed to terminate our promotion agreement. Following the termination, Arcutis plans to assume responsibility for sales and promotion in the pediatric and primary care settings.

Read more: https://t.co/jkjOc3WE3k